Predict your next investment

Non-Profit Foundation
i2b2transmart.org

See what CB Insights has to offer

Partners & Customers

5

About i2b2 tranSMART Foundation

The tranSMART Foundation is a non-profit organization that provides an open-source, cloud-based, data-sharing and analysis platform that enables scientists at more than 300 universities, disease foundations, pharmaceutical companies, and government agencies around the world to share pre-competitive data in a way that saves money and time in translating research findings into new therapies and diagnostic tools.

i2b2 tranSMART Foundation Headquarter Location

401 Edgewater Place Suite 600

Wakefield, Massachusetts, 1880,

United States

781-832-3144

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest i2b2 tranSMART Foundation News

Dell Technologies and i2b2 tranSMART Foundation Create Digital Twins to Treat Long-Haul COVID-19

May 7, 2021

BusinessWire India News summary COVID-19 Long haulers study to create personalized health risk scores and drug treatment recommendations based on patients’ unique medical history and genetics AI-driven research and digital twins will support hospitals and research centers globally and contribute to Dell’s goal to use technology and scale to advance health, education, and economic opportunity for 1 billion people by 2030   Full story: Dell Technologies (NYSE: DELL) is helping i2b2 tranSMART Foundation, a non-profit open-source research organization, mobilize huge amounts of global de-identified patient data to create virtual models of patients – known as digital twins – to treat impacts of long-haul COVID-19. Through Dell Technologies’ modern infrastructure, the i2b2 tranSMART community will use de-identified patient data to produce digital twins. Researchers can then perform millions of individualized treatment simulations on the digital twins to determine the best possible therapy option for patients, based on genetic background and medical history. To make this possible and provide the computational, artificial intelligence, machine learning, and advanced storage capabilities to generate digital twins, Dell Technologies built a data enclave – a secure data storage network – comprised of Dell EMC PowerEdge, PowerStore, and PowerScale storage systems, as well as VMware Workspace ONE and Boomi integration services. In the data enclave, researchers gather, store, and analyze data scattered across various monitoring systems and electronic health records and in the future will have the capability to update the digital twins with real-time clinical data collected through ventilator and cardiac monitors. “This project is a perfect example of the global research and technology community coming together to support people who are suffering from a condition that is not well understood,” said Jeremy Ford, vice president of strategic giving and social innovation, Dell Technologies. “Working together with the i2b2 tranSMART Foundation, we will apply our expertise and technology to build digital twins, share data, conduct simulations and analyses – using these insights to help understand and better treat patients with long-haul COVID.”   Initially, researchers will use the data enclave to power 70,000 patients’ tests, simulations, and analyses, which will be shared with the 4CE Consortium , an international coalition of more than 200 hospitals and research centers including data collaboratives across the US, France, Germany, Italy, Singapore, Spain, Brazil, India, and the United Kingdom. This effort has the potential to expand with data for up to two million digital twins in the next four years. Understanding and treating long-haul COVID An estimated 1 in 20 people  with COVID-19 are likely to experience long-term symptoms, ranging from profound fatigue, brain fog, headaches, cardiac arrhythmia, fevers, and shortness of breath. So-called long haulers suffer from what is known formally as Post-Acute Sequelae of SARS-CoV-2 (PASC). Little is known about why some continue to be affected after the virus has left the body or about the long-term impacts. To learn more, The National Institutes of Health recently  announced  the first phase of a four-year, billion-dollar initiative to support PASC research. Research on this condition requires colossal amounts of patient data. Working directly with the 4CE Consortium , the i2b2 tranSMART Foundation has supported the mobilization of data from a network of more than 200 institutions worldwide. To protect the privacy of patients, all data is de-identified before it is submitted to the 4CE Consortium. “At this stage, healthcare professionals are breaking new ground by developing and evaluating the efficacy of COVID-19 treatments,” said Dr. Shawn Murphy, i2b2 tranSMART Foundation board member. “This new AI-driven platform will help them use the explosion of research findings to deliver better care and precision treatments for their patients. By creating these digital twins, we are taking clinical research to a whole new level.”

i2b2 tranSMART Foundation Acquisitions

1 Acquisition

i2b2 tranSMART Foundation acquired 1 company. Their latest acquisition was The i2b2 Foundation on April 06, 2017.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

4/6/2017

$99M

Merger

1

Date

4/6/2017

Investment Stage

Companies

Valuation

$99M

Total Funding

Note

Merger

Sources

1

i2b2 tranSMART Foundation Partners & Customers

5 Partners and customers

i2b2 tranSMART Foundation has 5 strategic partners and customers. i2b2 tranSMART Foundation recently partnered with IBM on May 5, 2017.

Date

Type

Business Partner

Country

News Snippet

Sources

5/23/2017

Partner

United States

IBM and the tranSMART Foundation Bring Translational Medicine Data to Scientists

: IBM -RRB- , today announced their collaboration and the general availability of the tranSMART Foundation platform on IBM servers .

3

11/2/2016

Partner

United States

Subscribe to see more

Subscribe to see more

10

12/16/2015

Partner

United States

Subscribe to see more

Subscribe to see more

10

5/12/2014

Client

Canada, and Germany

Subscribe to see more

Subscribe to see more

10

4/22/2014

Vendor

Switzerland

Subscribe to see more

Subscribe to see more

10

Date

5/23/2017

11/2/2016

12/16/2015

5/12/2014

4/22/2014

Type

Partner

Partner

Partner

Client

Vendor

Business Partner

Country

United States

United States

United States

Canada, and Germany

Switzerland

News Snippet

IBM and the tranSMART Foundation Bring Translational Medicine Data to Scientists

: IBM -RRB- , today announced their collaboration and the general availability of the tranSMART Foundation platform on IBM servers .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

10

10

10

10

i2b2 tranSMART Foundation Team

1 Team Member

i2b2 tranSMART Foundation has 1 team member, including current Founder, Keith O Elliston.

Name

Work History

Title

Status

Keith O Elliston

Founder

Current

Name

Keith O Elliston

Work History

Title

Founder

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.